/
Oncology
Advanced or Metastatic Solid Tumor
22
Pipeline Programs↗
8
Active Trials↗
17
Companies Involved↗
Advanced or Metastatic Solid Tumor is an emerging landscape with 22 programs across 17 companies. The most active players are Taiho Pharmaceutical Co., Ltd., Evopoint Biosciences Inc., Affini-T Therapeutics, Inc..
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
Preclinical1
Phase 119
Phase 3
No programs
Approved
No programs
Analysis
Modality Breakdown
77%
Small molecule
17 of 22 classified programs — the dominant modality here.
Small molecule leads; the ring shows all 22 classified programs, each share of the total. Modality classified for 100% of 22 pipeline programs.
Analysis
Trial Status
17
clinical trials
Recruiting6 · 35%
Completed5 · 29%
Terminated4 · 24%
Active, not recruiting1 · 6%
Not yet recruiting1 · 6%
Clinical Trials
Trial Activity
17 trials
Page 1 of 2
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)